ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Get Free Report) was the target of a large decrease in short interest in the month of August. As of August 15th, there was short interest totalling 8,800 shares, a decrease of 35.8% from the July 31st total of 13,700 shares. Based on an average daily trading volume, of 8,200 shares, the short-interest ratio is currently 1.1 days.
Institutional Trading of ProShares UltraShort Nasdaq Biotechnology
A hedge fund recently bought a new stake in ProShares UltraShort Nasdaq Biotechnology stock. IMC Chicago LLC acquired a new stake in ProShares UltraShort Nasdaq Biotechnology (NASDAQ:BIS – Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 15,001 shares of the company’s stock, valued at approximately $271,000. IMC Chicago LLC owned approximately 3.19% of ProShares UltraShort Nasdaq Biotechnology at the end of the most recent quarter.
ProShares UltraShort Nasdaq Biotechnology Stock Up 0.2 %
BIS traded up $0.03 on Friday, hitting $14.48. The company had a trading volume of 64,168 shares, compared to its average volume of 14,180. The company’s fifty day moving average price is $15.40 and its 200 day moving average price is $17.16. ProShares UltraShort Nasdaq Biotechnology has a 1 year low of $14.07 and a 1 year high of $26.51.
ProShares UltraShort Nasdaq Biotechnology Cuts Dividend
ProShares UltraShort Nasdaq Biotechnology Company Profile
ProShares Ultra Nasdaq Biotechnology (the Fund) seeks investment results for a single day only, not for longer periods. The Fund seeks daily investment results, before fees and expenses, that correspond to twice (200%) the daily performance of the Index. The return of the Fund for a period longer than a single trading day will be the result of each day’s returns compounded over the period, which will very likely differ from twice (200%) the return of the Nasdaq Biotechnology Index (the Index) for that period.
Featured Stories
- Five stocks we like better than ProShares UltraShort Nasdaq Biotechnology
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Birkenstock’s Sudden Slide—Why It Might Be Your Next Big Win
- Using the MarketBeat Stock Split Calculator
- Why Dell Can Continue Winning in AI and Beyond
- How to Most Effectively Use the MarketBeat Earnings Screener
- Veeva’s Stock Jumps on Stellar Q2 Results—Don’t Miss Out
Receive News & Ratings for ProShares UltraShort Nasdaq Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProShares UltraShort Nasdaq Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.